GPX4 and COVID-19: In response to the ferroptosis manifestation of COVID-19, it has been suggested that drugs that enhance the GPX4-GSH axis, induce RTA and ACSL4 activity and ultimately lead to iron depletion in the unstable pool may be candidates for COVID-19 treatment (Fratta Pasini et al., 2021).